A detailed history of Cwm, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Cwm, LLC holds 389 shares of PCVX stock, worth $33,660. This represents 0.0% of its overall portfolio holdings.

Number of Shares
389
Previous 93 318.28%
Holding current value
$33,660
Previous $7,000 528.57%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$70.52 - $117.12 $20,873 - $34,667
296 Added 318.28%
389 $44,000
Q2 2024

Jul 09, 2024

BUY
$60.06 - $78.77 $3,423 - $4,489
57 Added 158.33%
93 $7,000
Q1 2024

Apr 05, 2024

BUY
$59.79 - $81.05 $1,016 - $1,377
17 Added 89.47%
36 $2,000
Q4 2023

Feb 01, 2024

SELL
$45.35 - $63.41 $907 - $1,268
-20 Reduced 51.28%
19 $1,000
Q3 2023

Oct 11, 2023

SELL
$46.0 - $53.1 $644 - $743
-14 Reduced 26.42%
39 $2,000
Q2 2023

Aug 03, 2023

BUY
$34.66 - $54.07 $1,525 - $2,379
44 Added 488.89%
53 $3,000
Q1 2023

Apr 28, 2023

SELL
$36.27 - $47.2 $398 - $519
-11 Reduced 55.0%
9 $0
Q4 2022

Feb 01, 2023

BUY
$20.58 - $47.95 $411 - $959
20 New
20 $1,000
Q1 2022

Apr 21, 2022

SELL
$17.46 - $26.36 $384 - $579
-22 Closed
0 $0
Q4 2021

Jan 31, 2022

BUY
$19.32 - $26.45 $425 - $581
22 New
22 $1,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.13B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.